Teva Pharmaceutical Industries (BSP:T1EV34) Cash Flow for Dividends: R$0 Mil (TTM As of Mar. 2026)


BSP:T1EV34 Teva Pharmaceutical Industries Ltd BSP:T1EV34
11 GF Score
Price R$89.28
GF Value R$52.51
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Cash Flow for Dividends?

Teva Pharmaceutical Industries BSP:T1EV34 11 Cash Flow for Dividends is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:T1EV34 with a GF Score™ of 11/100 and a GF Value™ of R$52.51 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Teva Pharmaceutical Industries's cash flow for dividends for the three months ended in Mar. 2026 was R$0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was R$0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Teva Pharmaceutical Industries Cash Flow for Dividends Related Terms

Teva Pharmaceutical Industries Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Cash Flow for Dividends Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:T1EV34
11GF Score
Teva Pharmaceutical Industries Ltd BSP:T1EV34
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of R$0 Mil mean?
Teva Pharmaceutical Industries (BSP:T1EV34) has a Cash Flow for Dividends of R$0 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Cash Flow for Dividends too high?
Teva Pharmaceutical Industries' current Cash Flow for Dividends is R$0 Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 11/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Cash Flow for Dividends compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Cash Flow for Dividends of R$0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Cash Flow for Dividends is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (BSP:T1EV34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$52.51, compared to a current price of R$89.28 — trading 70% above its estimated fair value. The current Cash Flow for Dividends is R$0 Mil. Teva Pharmaceutical Industries' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Cash Flow for Dividends is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of R$89.28 is trading 70% above its estimated GF Value™ of R$52.51. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for BSP:T1EV34:

  • Cash Flow for Dividends: R$0 Mil
  • GF Value™: R$52.51 vs. price of R$89.28 (70% above fair value)
  • GF Score™: 11/100 with 5 warning signs

No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
11GF Score

Get the complete analysis for BSP:T1EV34

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$89.28
Price
R$52.51
GF Value